Presentation TCT 2017 How to Align Incentives in the Cath Lab Presenter: Herbert D. Aronow October 31, 2017 REGISTER for free or LOG IN to view this content Policy & Practice Presentation TCT 2017 Training Up Next Presentation TCT 2017 FDA Perspectives on TAVR Label Expansion Using Real-World Evidence, Valve Degeneration, and Embolic Protection Devices Presenter: John C Laschinger October 31, 2017 More slides + Presentation TCT 2017 LOTUS TAVR Technology Review (Including EDGE) and Clinical Program Updates Presenter: Michael J. Reardon October 31, 2017 Presentation TCT 2017 Master Perspectives: Compared to Medical Therapy, Does CTO PCI Improve Prognosis, or Are the Main Benefits Symptomatic Improvement? Presenter: Barry D. Rutherford October 31, 2017 We Recommend
Presentation TCT 2017 FDA Perspectives on TAVR Label Expansion Using Real-World Evidence, Valve Degeneration, and Embolic Protection Devices Presenter: John C Laschinger October 31, 2017
Presentation TCT 2017 LOTUS TAVR Technology Review (Including EDGE) and Clinical Program Updates Presenter: Michael J. Reardon October 31, 2017
Presentation TCT 2017 Master Perspectives: Compared to Medical Therapy, Does CTO PCI Improve Prognosis, or Are the Main Benefits Symptomatic Improvement? Presenter: Barry D. Rutherford October 31, 2017